Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Mescaline

Mescaline is a naturally occurring psychedelic drug that is derived from certain cactus plants. It has been used for centuries by indigenous people in what is now Mexico for religious and spiritual purposes.

When consumed, mescaline produces powerful visual and auditory hallucinations as well as feelings of euphoria and detachment from reality. The effects of the drug can last for up to 12 hours.

Mescaline is a Schedule I controlled substance in the United States, meaning that it is illegal to manufacture, buy, possess, or use.

Recently Mescaline has been used as a tool in psychotherapy to help patients achieve a deeper understanding of their own psyche. Other uses of medical mescaline include treating alcoholism and post-traumatic stress disorder (PTSD).

Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression

Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30

September 22, 2022
Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials

World-class psychedelic biotech firm Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that Former FDA Director Dr. Thomas Laughren has

August 1, 2022
Journey-Colab-Announces-Appointment-of-Joel-A-Posener-MD-as-Chief-Medical-Officer Psychedeic-Chronicle-Logo-White
Psychedelic News

Journey Colab Announces Appointment of Joel A. Posener, MD as Chief Medical Officer

Biopharmaceutical company Journey Colab who are working to unlock the science of psychedelics and build a new model for addiction treatment recently

July 20, 2022

Recent Posts

  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial
  • Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio
  • Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression

Recent Comments

No comments to show.

Popular

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS